viral
infect
remain
one
import
complic
follow
allogen
hsct
report
compar
viru
infect
differ
donor
type
pediatr
patient
retrospect
analyz
viral
infect
outcom
one
hundr
seventyon
pediatr
patient
median
year
underw
allogen
hsct
match
relat
donor
mrd
n
hla
allelematch
unrel
donor
n
hla
allelematch
unrel
donor
n
haploident
donor
n
pcr
screen
bk
viru
adenoviru
epsteinbarr
viru
parvoviru
human
herpesviru
cmv
perform
routin
weekli
infect
year
identifi
separ
bk
viru
cmv
reactiv
significantli
low
mrd
transplant
patient
p
p
respect
incid
viru
infect
haplohsct
found
statist
differ
os
found
affect
one
multipl
viru
infect
p
p
despit
antivir
prophylaxi
treatment
posttranspl
viral
infect
associ
reduc
overal
surviv
haplohsct
compar
mud
transplant
set
viral
infect
larger
studi
group
prospect
studi
need
confirm
observ
k
e
w
r
outcom
pediatr
stem
cell
transplant
viru
infect
introduct
delay
immun
reconstitut
viral
infect
remain
signific
caus
morbid
mortal
follow
allogen
hsct
natur
histori
immun
reconstitut
alter
allogen
transplant
gvhd
well
immunosuppress
therapi
although
viral
infect
also
common
mrdhsct
risk
sever
diseas
higher
mud
haplohsct
due
sever
depress
cellmedi
immun
respons
addit
celldeplet
agent
atg
condit
regimen
mud
transplant
associ
reduc
incid
gvhd
increas
risk
delay
immun
reconstitut
also
tcr
deplet
prophylaxi
gvhd
achiev
signific
success
haploident
hsct
associ
increas
risk
viral
infect
aim
studi
compar
incid
viru
infect
outcom
children
underw
hsct
mrd
haploident
donor
age
median
rang
male
retrospect
analyz
viral
infect
outcom
one
hundr
seventyon
pediatr
patient
median
year
underw
allogen
hsct
januari
septemb
patient
divid
four
subgroup
patient
transplant
mrd
n
hla
allelemud
n
hla
allelemud
n
haploident
donor
n
patient
characterist
summar
pairedsampl
test
use
comparison
depend
variabl
twotail
p
valu
consid
statist
signific
kaplanmei
method
use
surviv
analysi
one
hundr
seventyon
pediatr
patient
undergo
hsct
enrol
studi
median
durat
followup
month
rang
month
main
diagnosi
hla
dispar
donor
type
condit
regimen
use
corticosteroid
atg
median
cell
graft
engraft
day
neutrophil
platelet
lymphocyt
lymphocyt
count
day
day
lymphocyt
count
exist
acut
chronic
gvhd
accord
donor
type
summar
tabl
achiev
day
earlier
patient
receiv
haplohsct
patient
receiv
mrd
mud
hsct
differ
statist
differ
tabl
lymphocyt
count
day
day
lymphocyt
count
greater
significantli
differ
four
group
tabl
immunophenotyp
analysi
reveal
progress
slow
increas
lymphocyt
subset
count
day
later
tabl
tabl
overal
surviv
influenc
one
multipl
viral
infect
p
p
trm
day
statist
signific
four
group
trm
end
followup
found
statist
signific
p
signific
especi
promin
mrd
haplotransplant
p
p
p
comparison
overal
surviv
end
followup
four
group
associ
significantli
better
surviv
mrd
group
log
rank
test
p
viral
infect
due
impair
immun
reconstitut
remain
caus
morbid
mortal
hsct
patient
incid
viral
infect
best
indic
immun
recoveri
studi
pediatr
patient
second
largest
studi
report
incid
viru
infect
children
follow
allogen
hsct
found
viral
infect
especi
common
first
knowledg
studi
studi
compar
viral
incid
haplohsct
mrdmud
hsct
detect
incid
cmv
reactiv
ofmrd
patient
haploand
hsct
recipi
posit
cmv
reactiv
differ
explain
ethnic
geograph
differ
cmv
seropreval
turkish
popul
countri
seropreval
rate
age
group
year
detect
respect
bk
viru
second
seen
viru
studi
bk
viru
frequent
presenc
mud
haplohsct
cord
blood
transplant
gvhd
advanc
age
persist
thrombocytopenia
also
found
bk
viru
frequent
among
recipi
haplohsct
mrd
graft
adv
increasingli
recogn
import
pathogen
recipi
allogen
hsct
report
mortal
patient
sustain
high
adv
dna
level
plasma
remark
high
vari
differ
studi
studi
haplohsct
patient
hsct
patient
hsct
patient
develop
adv
infect
ptld
occur
patient
hsct
found
nine
patient
show
ebv
reactiv
interestingli
detect
lack
ptld
report
also
kanakri
et
al
